en Oncology Oncology Original Article Original Article <span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:14.5pt"><b><i><span style="color:blue">Background</span></i></b><i><span style="color:blue">:</span></i> Breast cancer management depends on molecular subtypes. The aim was to compare disease-free survival (DFS) among the different subgroups. Overall survival (OS) is a secondary endpoint.<b> </b></span><br> <span style="line-height:14.5pt"><b><i><span style="color:blue">Methods:</span></i></b> This cross-sectional study was done on breast cancer women that were treated in our center, from 2009 to 2015. Breast cancer molecular subtypes were determined based on clinicopathological criteria recommended by St Gallen and include; luminal A, luminal B Her- 2-neu positive, luminal B Her-2-neu negative, Her-2 enriched and triple negative. Patients with metastasis at diagnosis or those without follow-up were excluded. Patients were followed-up from 12 to 132 months. Cox regression analysis was used for analogy of DFS and OS between the subgroups.</span><br> <span style="line-height:14.5pt"><b><i><span style="color:blue">Results:</span></i></b> Out of three hundred patients, 221 were enrolled with median age of 47 years old (26 to 83). Luminal B, Her-2 negative was the most common subgroup with 83 patients (35.5%). Five and 10 years PFS were 95% and 81% for luminal A, were 95.5% and 92% for luminal B Her-2 positive, were 92% and 91% for luminal B Her-2 negative, were both 84% for triple negative and were 76% and 74% for Her-2 enriched subgroups, respectively. With multivariate analysis, the stage of tumor (HR=5.9 CI=1.06-32.69) and triple negative subgroup (HR=5.2 CI=1.33-20.31) were independent factors for recurrence.</span><br> <span style="line-height:14.5pt"><b><i><span style="color:blue">Conclusion</span></i></b><i><span style="color:blue">:</span></i> Based on the results of this study, the triple-negative breast cancer and possibly Her-2 enriched subgroup have a shorter DFS than luminal breast cancers. Also, the stage of tumor is an independent factor for recurrence.</span></span></span><br> &nbsp; molecular subtypes, breast cancer, progression free survival, overall survival. 141 150 http://caspjim.com/browse.php?a_code=A-10-117-4&slc_lang=en&sid=1 Maryam Esmati maryamesmati@gmail.com 100319475328460054894 0009-0003-4714-3391 No Student research committee, Babol university of medical sciences, Babol, Iran Fatemeh Monfaredi fateme.monfaredi@gmail.com 100319475328460054895 0009-0005-7377-1492 No Student research committee, Babol university of medical sciences, Babol, Iran Mohsen Vakili Sadeghi mvakili89@gmail.com 100319475328460054896 100319475328460054896 Yes Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Mohammad Ranaee drm.ranaee@yahoo.com 100319475328460054897 100319475328460054897 No Department of pathology, Babol University of Medical Sciences, Babol, Iran Hossein ghorbani Ghorbani7958@yahoo.com 100319475328460054898 100319475328460054898 No Department of pathology, Babol University of Medical Sciences, Babol, Iran Sadegh Sedaghat sadeghsedaghat9@gmail.com 100319475328460054899 100319475328460054899 No Department of Internal Medicine, Babol University of Medical Sciences, Babol, Iran Hemmat Gholinia H_gholinia@yahoo.com 100319475328460054900 100319475328460054900 No Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran